Daiwa Securities Group Raises Johnson & Johnson (NYSE:JNJ) Price Target to $246.00

Johnson & Johnson (NYSE:JNJ) had its price objective lifted by Daiwa Securities Group from $237.00 to $246.00 in a research note issued on Thursday,MarketScreener reports. The firm currently has an “outperform” rating on the stock. Daiwa Securities Group’s target price indicates a potential upside of 3.99% from the company’s previous close.

Several other research firms have also recently weighed in on JNJ. Wall Street Zen cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Leerink Partners upped their price target on shares of Johnson & Johnson from $232.00 to $252.00 and gave the company a “market perform” rating in a research note on Wednesday. Stifel Nicolaus lifted their price objective on shares of Johnson & Johnson from $220.00 to $250.00 and gave the stock a “hold” rating in a research note on Wednesday. Sanford C. Bernstein boosted their price objective on shares of Johnson & Johnson from $225.00 to $251.00 and gave the company a “market perform” rating in a report on Wednesday. Finally, Morgan Stanley set a $283.00 target price on shares of Johnson & Johnson in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $251.52.

Johnson & Johnson Stock Down 0.9%

Shares of JNJ opened at $236.55 on Thursday. The firm’s 50-day simple moving average is $241.67 and its 200 day simple moving average is $216.53. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03. The firm has a market cap of $569.77 billion, a P/E ratio of 27.35, a price-to-earnings-growth ratio of 2.40 and a beta of 0.34. Johnson & Johnson has a 52 week low of $146.12 and a 52 week high of $251.71.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, beating the consensus estimate of $2.68 by $0.02. The company had revenue of $24.06 billion for the quarter, compared to the consensus estimate of $23.60 billion. Johnson & Johnson had a return on equity of 32.75% and a net margin of 21.83%.The firm’s revenue for the quarter was up 9.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 22,623 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the completion of the transaction, the executive vice president directly owned 26,769 shares in the company, valued at $6,540,469.77. The trade was a 45.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Vanessa Broadhurst sold 6,197 shares of the company’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the sale, the executive vice president owned 23,003 shares of the company’s stock, valued at $5,598,700.17. The trade was a 21.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 30,142 shares of company stock valued at $7,360,528 over the last 90 days. Corporate insiders own 0.16% of the company’s stock.

Institutional Trading of Johnson & Johnson

Institutional investors and hedge funds have recently modified their holdings of the business. Blueline Advisors LLC bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at approximately $25,000. Abich Financial Wealth Management LLC acquired a new stake in Johnson & Johnson in the third quarter valued at approximately $26,000. Cresta Advisors Ltd. acquired a new stake in Johnson & Johnson in the fourth quarter valued at approximately $26,000. Clayton Financial Group LLC bought a new stake in shares of Johnson & Johnson during the third quarter worth $28,000. Finally, DecisionPoint Financial LLC increased its holdings in shares of Johnson & Johnson by 104.2% during the fourth quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock worth $30,000 after buying an additional 75 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Q1 results beat expectations — revenue of $24.06B and EPS above estimates — and management raised 2026 guidance, underpinning confidence in near‑term growth. Johnson & Johnson Raises 2026 Outlook
• Positive Sentiment: Management laid out a plan to drive record revenue this year and is explicitly targeting ~$100B in annual sales — a clear growth signal that supports higher valuation expectations. How J&J plans to hit $100B in revenue this year
• Positive Sentiment: Dividend and shareholder returns: J&J announced a quarterly dividend increase (64th consecutive annual raise), reinforcing its income appeal to investors. Johnson and Johnson Raises Dividend
• Positive Sentiment: Several firms lifted price targets and ratings after the quarter (Goldman, Wells Fargo, Raymond James, others), adding buy‑side momentum. Analysts Boost Forecasts on J&J
• Neutral Sentiment: J&J agreed to sell rights to a gene‑therapy asset (botaretigene sparoparvovec) to MeiraGTx — a non‑core asset sale that could free capital but has limited immediate revenue impact. MeiraGTx acquisition of bota-vec
• Neutral Sentiment: Corporate engagement: Management will present at the Bank of America Healthcare Conference (May 12) — a routine investor event where management may provide additional detail on growth drivers. J&J to Participate in BOA Healthcare Conference
• Negative Sentiment: Near‑term risks: investors remain wary of biosimilar competition and a steep decline in legacy drug (Stelara) sales; free cash flow also fell in the quarter, which could cap multiple expansion. This helps explain occasional intraday weakness despite the beat. Dow Jones’ J&J Slips Despite Beating First-Quarter Calls

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.